JAMA Publishes Study Results on Efficacy of the Bard Agento I.C. Silver-Coated Endotracheal Tube in Preventing Ventilator-Associated Pneumonia

C. R. Bard, Inc. (NYSE: BCR) announced the publication of the North American Silver-Coated Endotracheal Tube (NASCENT) clinical study results in the August 20, 2008 edition of the Journal of the American Medical Association (JAMA). The NASCENT study - which enrolled 2,003 patients in 54 hospitals - evaluated the efficacy of the Agento(R) I.C. silver-coated endotracheal tube (ETT) in the reduction of microbiologically confirmed ventilator-associated pneumonia (VAP). The U.S. Food and Drug Administration cleared the Agento(R) I.C. silver-coated ETT in November 2007 for the prevention of VAP in patients intubated for 24 hours or longer. As reported in JAMA, the NASCENT study demonstrated that...

Want to see the full article?

• Purchase this article for only $3.00